



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/741,718	12/20/2000	Herve Buzot	PPC-767	7536

7590 06/10/2003
Philip S. Johnson, Esq.
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003

EXAMINER

ANDERSON, CATHARINE L

ART UNIT	PAPER NUMBER
----------	--------------

3761

DATE MAILED: 06/10/2003

15

Please find below and/or attached an Office communication concerning this application or proceeding.

Y.K.

Office Action Summary

Application No.

09/741,718

Applicant(s)

BUZOT, HERVE

Examiner

C. Lynne Anderson

Art Unit

3761

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 17 March 2003.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-36 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-22 and 26-36 is/are rejected.
- 7) ☒ Claim(s) 23-25 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 14. 6) ☐ Other:

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 17 March 2003 has been entered.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-19 and 27 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1 and 27 recite the limitation "having a bulk density within about 20% of the bulk density of a system formed of the absorbent material at its maximum volume capacity". It is unclear what a system formed of the absorbent material at its maximum volume capacity. The instant specification describes the determination the bulk density of the tablets when the volume capacity of the tablets is within 20% of the maximum volume capacity. This is shown in table 2a as Density @ 80% Max. C_v. Table 2a shows the density at 80% of the maximum volume capacity, rather than a density within 20% of maximum volume capacity. Are the instant claims intending to disclose tablets

Art Unit: 3761

having a certain bulk density when the volume capacity of the tablets is within 20% of their maximum volume capacity? If this interpretation of the instant specification and the intended meaning of the claim limitation quoted above, the applicant is urged to contact the examiner to clarify the instant invention.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 4-6, 8, 13, 15, 16, 19, 26-30, 34, and 35 are rejected under 35 U.S.C. 102(b) as being anticipated by Reeves et al. (4,278,088).

Reeves discloses an absorbent article, as shown in figure 1, comprising an overwrap 1 and absorbent material 2. The overwrap 1 is fluid-permeable, as disclosed in column 1, lines 55-57. The absorbent material 2 comprises a plurality of compressed, fibrous tablets, as disclosed in column 1, lines 53-55. The tablets inherently have a bulk density at within 20% of their maximum volume capacity, though Reeves remains silent as to the value of the bulk density.

With respect to claims 4-6 and 8, the absorbent material 2 comprises cellulosic material, as disclosed in column 2, lines 39-42. Cellulose is bondable by nature, and its chemical structure permits it to form hydrogen bonds.

With respect to claim 13, the overwrap 1 comprises a nonwoven material, as disclosed in column 3, lines 3-5.

Art Unit: 3761

With respect to claims 15 and 16, the overwrap 1 is a liquid-permeable bag, as disclosed in column 1, lines 55-57.

With respect to claim 19, the absorbent article is a tampon, as disclosed in claim 1.

With respect to claims 26 and 27, the finished absorbent article disclosed by Reeves is made by the claimed method, as described in column 2, lines 56-57. Carlucci discloses a fibrous, absorbent material 50 which is compressed into tablets and placed into an overwrap 1. The overwrap 1 is then sealed by closure 7.

With respect to claim 28, the overwrap 1 is placed in a tampon applicator I, as shown in figure 2.

With respect to claim 29, the overwrap 1 is a bag, as disclosed in column 1, lines 55-57.

With respect to claim 30, the overwrap 1 is a nonwoven material, as disclosed in column 3, lines 3-5.

With respect to claim 34, a withdrawal string 5 is attached to the bag formed by overwrap 1, as shown in figure 1.

With respect to claim 35, the absorbent article of claim 34 is placed in a tampon applicator I, as shown in figure 2.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the

Art Unit: 3761

invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claim 14 is rejected under 35 U.S.C. 103(a) as being unpatentable over Reeves et al. (4,278,088) as applied to claim 1 above, and further in view of Foley et al. (5,817,077).

Reeves discloses all aspects of the claimed invention with the exception of an apertured film overwrap. Foley discloses an absorbent article having an apertured film overwrap, as disclosed in column 4, lines 37-43. The purpose of this is to reduce the amount of moisture absorbed from the epithelial tissue, thus keeping the tissue from drying out, as described in column 2, lines 54-61.

It would therefore be obvious to one of ordinary skill in the art at the time of invention to wrap the absorbent article of Reeves with the apertured film of Foley to prevent the epithelial tissue of the wearer from drying out.

Claims 20-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gellert (4,475,911).

Gellert discloses all aspects of the claimed invention but remains silent as to the bulk density of the tablets. Gellert discloses an absorbent article in the form of a tampon for intravaginal use, as shown in figure 8, containing a plurality of tablets 39 of compressed, fibrous material, as disclosed in column 10, lines 6-11. It would have been an obvious matter of design choice to have the bulk density of the tablets be between about 0.8 and about 1.2 g/cc, since the applicant has not disclosed the density being between about 0.8 and about 1.2 g/cc solves any stated problem or serves any particular purpose.

Art Unit: 3761

Allowable Subject Matter

Claims 23-25 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claims 2, 3, 7, 9-12, and 17-18 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112, second paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to C. Lynne Anderson whose telephone number is (703) 306-5716. The examiner can normally be reached on Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Weilun Lo can be reached on (703) 308-1957. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3590 for regular communications and (703) 306-4520 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1148.

UAA
cla
June 5, 2003


WEILUN LO
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 3700